Press release
Adrenoleukodystrophy Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market and Companies by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, more
Adrenoleukodystrophy Clinical Trials
"Adrenoleukodystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenoleukodystrophy Market.
The Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Adrenoleukodystrophy Pipeline Report: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Companies across the globe are diligently working toward developing novel Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years.
• Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the Adrenoleukodystrophy treatment
• Emerging Adrenoleukodystrophy therapies such as - ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the Adrenoleukodystrophy market in the coming years.
• In February 2024, The manufacturers of Nezglyal, Minoryx Therapeutics and Neuraxpharm Pharmaceuticals, plan to request a re-examination for conditional approval. This follows the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommendation to refuse marketing authorisation for Nezglyal (leriglitazone), an innovative orally bioavailable and selective peroxisome proliferator-activated receptor gamma agonist, developed for the treatment of cerebral adrenoleukodystrophy (cALD).
Adrenoleukodystrophy Overview
Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the adrenal glands, the nervous system, and the myelin sheath of nerve cells in the brain. It primarily affects males and is caused by mutations in the ABCD1 gene located on the X chromosome.
Get a Free Sample PDF Report to know more about Adrenoleukodystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:
• ABX-002: Autobahn Therapeutics
• VK0214: Viking Therapeutics
• SBT101: SwanBio Therapeutics
• PXL065: Poxel SA
• PXL770: Poxel SA
• Leriglitazone : Minoryx Therapeutics
• OP101 : Orpheris
• Leriglitazone (MIN102): Minoryx Therapeutics
Route of Administration
Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide
Adrenoleukodystrophy Pipeline Therapeutics Assessment
• Adrenoleukodystrophy Assessment by Product Type
• Adrenoleukodystrophy By Stage and Product Type
• Adrenoleukodystrophy Assessment by Route of Administration
• Adrenoleukodystrophy By Stage and Route of Administration
• Adrenoleukodystrophy Assessment by Molecule Type
• Adrenoleukodystrophy by Stage and Molecule Type
DelveInsight's Adrenoleukodystrophy Report covers around 11+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Adrenoleukodystrophy product details are provided in the report. Download the Adrenoleukodystrophy pipeline report to learn more about the emerging Adrenoleukodystrophy therapies
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Adrenoleukodystrophy Therapeutics Market include:
Key companies developing therapies for Adrenoleukodystrophy are - AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.
Adrenoleukodystrophy Pipeline Analysis:
The Adrenoleukodystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenoleukodystrophy Treatment.
• Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Adrenoleukodystrophy drugs and therapies
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Adrenoleukodystrophy Pipeline Market Drivers
• Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the Adrenoleukodystrophy Market.
Adrenoleukodystrophy Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Adrenoleukodystrophy Market growth.
Scope of Adrenoleukodystrophy Pipeline Drug Insight
• Coverage: Global
• Key Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others
• Key Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others
• Adrenoleukodystrophy Therapeutic Assessment: Adrenoleukodystrophy current marketed and Adrenoleukodystrophy emerging therapies
• Adrenoleukodystrophy Market Dynamics: Adrenoleukodystrophy market drivers and Adrenoleukodystrophy market barriers
Request for Sample PDF Report for Adrenoleukodystrophy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1 Adrenoleukodystrophy Report Introduction
2 Adrenoleukodystrophy Executive Summary
3 Adrenoleukodystrophy Overview
4 Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment
5 Adrenoleukodystrophy Pipeline Therapeutics
6 Adrenoleukodystrophy Late Stage Products (Phase II/III)
7 Adrenoleukodystrophy Mid Stage Products (Phase II)
8 Adrenoleukodystrophy Early Stage Products (Phase I)
9 Adrenoleukodystrophy Preclinical Stage Products
10 Adrenoleukodystrophy Therapeutics Assessment
11 Adrenoleukodystrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Adrenoleukodystrophy Key Companies
14 Adrenoleukodystrophy Key Products
15 Adrenoleukodystrophy Unmet Needs
16 Adrenoleukodystrophy Market Drivers and Barriers
17 Adrenoleukodystrophy Future Perspectives and Conclusion
18 Adrenoleukodystrophy Analyst Views
19 Appendix
20 About DelveInsight
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-bronchitis-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Progressive Multiple Sclerosis Market: https://www.delveinsight.com/report-store/chronic-progressive-multiple-sclerosis-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-cle-market
• Encephalitis Market: https://www.delveinsight.com/report-store/encephalitis-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Bacteremia Market: https://www.delveinsight.com/report-store/bacteremia-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
• Cardiac Insufficiency Market: https://www.delveinsight.com/report-store/congestive-heart-failure-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occlusion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Refractory Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Egfr Non-small Cell Lung Cancer Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Endometriosis Pain Market: https://www.delveinsight.com/report-store/endometriosis-pain-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adrenoleukodystrophy Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market and Companies by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, more here
News-ID: 3661693 • Views: …
More Releases from DelveInsight Business Research
Global Medical Device Contract Manufacturing Market to reach USD 79,333.13 milli …
According to DelveInsight's analysis, The increasing prevalence of chronic and infectious diseases is fueling a steady demand for innovative, high-quality medical devices, prompting companies to accelerate their development initiatives. In response, leading medical device firms are boosting R&D investments and partnering with Contract Manufacturing Organizations (CMOs) to lower costs and shorten time-to-market. Alongside rapid technological advancements, this trend is driving a strong global pipeline of medical devices and facilitating regulatory…
Global Intraocular Lens Market Poised to Expand at a CAGR of 6.12% Through 2032, …
According to DelveInsight's analysis, The intraocular lens (IOL) market is experiencing strong growth driven by the increasing prevalence of eye conditions such as cataracts, presbyopia, and astigmatism, which are boosting the need for corrective surgical procedures. This growth is further supported by rising awareness and better accessibility to eye care services, especially in emerging economies, enabling timely diagnosis and treatment. Continuous innovations in lens materials and designs-such as multifocal, toric,…
Global CDMO Market to reach USD 233.71 billion in 2024 at a CAGR of 7.25% by 203 …
According to DelveInsight's analysis, The Contract Development and Manufacturing Organization (CDMO) market is witnessing robust growth, fueled by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and diabetes, which has boosted demand for innovative therapies. Additionally, the growing need for biologics and small-molecule drugs, given their efficacy in managing complex conditions, is driving the expansion of outsourced drug development and manufacturing services.
DelveInsight's "Contract Development Manufacturing Organization Market…
Global Mechanical Thrombectomy Devices Market to reach USD 849.70 million in 202 …
According to DelveInsight's analysis, The demand for mechanical thrombectomy devices is being driven by several key factors highlighting robust market growth. Chief among these is the increasing global prevalence of neurological and vascular conditions, such as acute ischemic stroke and deep vein thrombosis, which fuels the need for prompt and effective treatments. Moreover, patients and healthcare providers are showing a rising preference for minimally invasive and non-surgical therapeutic options.
DelveInsight's "Mechanical…
More Releases for Adrenoleukodystrophy
Adrenoleukodystrophy Treatment Market: Transforming Rare Disease Therapeutics
The adrenoleukodystrophy treatment market was valued at approximately USD 1.1 billion in 2023 and is anticipated to reach around USD 2.4 billion by 2033, growing at a CAGR of 8.1% from 2024 to 2033.
The adrenoleukodystrophy (ALD) treatment market represents a critical segment within the rare disease therapeutics landscape, addressing one of the most challenging genetic disorders affecting the nervous system and adrenal glands. This X-linked genetic condition, caused by mutations…
X Linked Adrenoleukodystrophy Market Regional Analysis & Global Forecast to 2025 …
The X-Linked Adrenoleukodystrophy Market Is Set To Grow At An Estimated CAGR Of 14% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $4.5 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of X Linked Adrenoleukodystrophy market goods. The market study excludes key regions that are accelerating marketization. This…
X-linked Adrenoleukodystrophy Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "X-Linked Adrenoleukodystrophy Pipeline Insight, 2024," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-Linked Adrenoleukodystrophy (X-ALD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in X-linked adrenoleukodystrophy Research. Learn more…
Adrenoleukodystrophy Pipeline Outlook, Clinical Trials, FDA Approvals, and Compa …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy pipeline…
Adrenoleukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and C …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy…
Adrenoleukodystrophy Market Size, Market Trends & Analysis till 2033
Market Overview:
The adrenoleukodystrophy market is expected to exhibit a CAGR of 1.84% during 2023-2033. The adrenoleukodystrophy market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major…
